➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKinsey
Medtronic
Baxter
Moodys

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,435,404

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,435,404 protect, and when does it expire?

Patent 10,435,404 protects TURALIO and is included in one NDA.

This patent has eight patent family members in eight countries.

Summary for Patent: 10,435,404
Title:Formulations of a compound modulating kinases
Abstract: Provided are compositions comprising Compound I having the following structure: ##STR00001## or a pharmaceutically acceptable salt thereof, and a solubilizing agent; methods of making the same; and methods of using the same.
Inventor(s): Ibrahim; Prabha N. (Mountain View, CA), Rezaei; Hamid (Berkeley, CA), Visor; Gary Conard (Castro Valley, CA), Kamo; Tomoari (Tokyo, JP), Yamakose; Hiroshi (Tokyo, JP)
Assignee: Plexxikon Inc. (Berkeley, CA) Daiichi Sankyo Company, Limited (Tokyo, JP)
Application Number:16/043,821
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Process; Dosage form;

Drugs Protected by US Patent 10,435,404

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Daiichi Sankyo Inc TURALIO pexidartinib hydrochloride CAPSULE;ORAL 211810-001 Aug 2, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,435,404

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2018307910   Start Trial
Brazil 112019028235   Start Trial
Canada 3070505   Start Trial
China 110944670   Start Trial
European Patent Office 3658189   Start Trial
South Korea 20200032683   Start Trial
Taiwan 201907920   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Colorcon
Merck
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.